NewLink Genetics Corp (NASDAQ:NLNK)’s share price was down 5.8% during trading on Tuesday . The company traded as low as $1.43 and last traded at $1.47, approximately 1,184,716 shares were traded during trading. An increase of 126% from the average daily volume of 523,706 shares. The stock had previously closed at $1.56.
NLNK has been the topic of a number of recent research reports. Bank of America lowered NewLink Genetics from a “neutral” rating to an “underperform” rating in a research report on Friday, January 3rd. ValuEngine raised shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Sunday, February 16th.
The stock’s 50 day moving average price is $1.80 and its two-hundred day moving average price is $1.69. The stock has a market cap of $58.28 million, a price-to-earnings ratio of -1.32 and a beta of 1.24.
NewLink Genetics Company Profile (NASDAQ:NLNK)
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.
Featured Article: How interest rates affect municipal bond prices
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.